Enzyvant announces first-ever data on burden of illness and costs of supportive care for pediatric congenital athymia patients. Learn more

Newsroom



No posts found!

Enzyvant Appoints Jeb Ledell as Chief Operating Officer

Enzyvant Newsrooom | October 2019

Reading Time: 2 minutes

Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer

Enzyvant Newsrooom | February 2019

Reading Time: 2 minutes

Enzyvant Receives FDA Rare Pediatric Disease Designation for Investigational Therapy RVT-802

Enzyvant Newsrooom | September 2017

Reading Time: 3 minutes

Rare Disease Day

Enzyvant Newsrooom | February 2017

Reading Time: < 1 minute

RARE in the Square

Enzyvant Newsrooom | January 2017

Reading Time: < 1 minute

Enzyvant to Develop Novel Biologic Therapy for Complete DiGeorge Syndrome

Enzyvant Newsrooom | January 2017

Reading Time: 2 minutes

Contact us for more information